Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms.

Critical reviews in oncology/hematology - 1 Dec 2024

Wagh Hrushikesh, Bhattacharya Sankha

Abstract excerpt

Biliary tract cancers (BTCs) are aggressive malignancies with a dismal prognosis that require intensive targeted therapy. Approximately 10 % of BTCs have PBRM1 mutations, which impede DNA damage repair pathways and make cancer cells more susceptible to DNA-damaging chemicals. This review focus on development of poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles targeting delivery system to selectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Damage

Share to DNA Repair

Share to Molecular Targeted Therapy

Share to Nanoparticles

Share to Nuclear Proteins

Share to Polymers

Source

Identifiers

PMID: 39255911
DOI: 10.1016/j.critrevonc.2024.104505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms.PMID 39255911Read ↗

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair systemSemantic proximity Read ↗

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision MedicineSemantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Rational development of combination therapies for biliary tract cancers.Semantic proximity Read ↗

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?Semantic proximity Read ↗

A Targeted Octahedral DNA Nanostructure Co-delivers siME3 and Doxorubicin to Enhance Collateral Lethality in ME2-Deficient Pancreatic CancerSemantic proximity Read ↗

Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studiesSemantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

An overview of targeted cancer therapySemantic proximity Read ↗

Polymeric Carriers for Delivery of RNA Cancer TherapeuticsSemantic proximity Read ↗

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.